Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX 4 25 5 SULFITE FREE IN DEXTROSE 5 IN PLASTIC CONTAINER versus KABIVEN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX 4 25 5 SULFITE FREE IN DEXTROSE 5 IN PLASTIC CONTAINER versus KABIVEN IN PLASTIC CONTAINER.
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER vs KABIVEN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLINIMIX 4.25/5 is a parenteral nutrition solution providing amino acids and dextrose for protein synthesis and energy metabolism. Amino acids serve as substrates for protein synthesis, while dextrose provides a source of glucose for cellular energy production via glycolysis and oxidative phosphorylation.
Kabiven is a parenteral nutrition formulation that provides a balanced mixture of amino acids, dextrose, and lipids to meet nutritional requirements. The amino acids serve as building blocks for protein synthesis, dextrose provides a carbohydrate source for energy, and lipids supply essential fatty acids and additional energy. Electrolytes are included to maintain fluid and electrolyte balance.
IV, dosage individualized based on protein and energy requirements. Typical adult dose: 1.5 g/kg/day of amino acids (4.25% solution) as part of total parenteral nutrition, infused at a rate not exceeding 0.1 g/kg/hour.
Intravenous infusion. Adult dose based on nutritional needs: typically 0.8-1.5 g amino acids/kg/day, 0.8-1.5 g lipids/kg/day, and 2-4 g dextrose/kg/day. Maximum infusion rate: 1.7 mL/kg/hour (Kabiven Peripher) or 2.6 mL/kg/hour (Kabiven Central).
None Documented
None Documented
Amino acids: variable, with terminal half-life of individual amino acids ranging from 0.5 to 3 hours. Clinical context: continuous infusion maintains steady-state levels; used for nutritional support.
Variable; amino acids: 0.5–1 h; lipids: 0.5–1 h (intralipid clearance); glucose: rapid. No true terminal half-life as a mixture.
The components (amino acids and dextrose) are metabolized; excess nitrogen is excreted renally as urea (about 85-90%), with minor fecal loss (<5%). Dextrose is fully metabolized to CO2 and water, with negligible renal excretion.
Renal: <3% unchanged; primarily metabolized via protein catabolism; nitrogen excretion is renal (urea, ammonia); fat emulsion components are cleared by the reticuloendothelial system and metabolized. Biliary/fecal: negligible.
Category C
Category C
Parenteral Nutrition
Parenteral Nutrition